Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Sunitinib Treatment Of Renal Adjuvant Cancer (S-trac): A Randomized Double-blind Phase 3 Study Of Adjuvant Sunitinib Vs. Placebo In Subjects At High Risk Of Recurrent Rcc

NCT00375674 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00375674
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00375674 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Sunitinib Treatment Of Renal Adjuvant Cancer (S-trac): A Randomized Double-blind Phase 3 Study Of Adjuvant Sunitinib Vs. Placebo In Subjects At High Risk Of Recurrent Rcc
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Completed
Start date
August 1, 2007
Completion date
September 7, 2017
Enrollment
674 (actual)
Sites
115

Conditions

As the registry lists them; a condition with its own page is linked.

kidney neoplasms